Eone-Diagnomics Genome Center (hereinafter EDGC) announced on May 14 that its financial results for the first quarter reached 11.2 billion won(consolidated). This is the highest quarterly sales since the company’s listing in last July and 52% of the previous year’s total sales. 

Non-invasive prenatal testing (NICE) sales for the first quarter of 2019 increased about 50%, newborn screening (bebegene) sales increased about 28%, and disease prediction testing (gene2me Plus) increased about 450% compared to last year’s first quarter.

Meanwhile, the company explained that 2.1 billion won in operating losses (consolidated) was incurred due to the development and upgrading of services and increased operating marketing and labor costs to advance into overseas markets.

In order to achieve 50 billion won in sales this year, EDGC plans to expand domestic and overseas sales of genome-based services by ▲releasing affiliate service, such as establishment of precision medical service, through partnership ▲localization of services to overseas market by strategic approach and cost adjustment.

Jae-hyung Yoo, vice president of EDGC, said “The company made 11.2 billion won in the first quarter, which is 52% of total sales of last year’s 21.4 billion won. It is expected that the company’s competitiveness through continuous research and development of genetic testing services is effectively positioning itself in the global market. EDGC will take on the role of game changer to lead the global genomics market.”